Page last updated: 2024-12-10
via 2291
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
atreleuton: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3086671 |
| CHEMBL ID | 59356 |
| SCHEMBL ID | 2108309 |
| MeSH ID | M0547327 |
Synonyms (43)
| Synonym |
|---|
| atreleuton |
| {3-[5-(4-fluoro-benzyl)-thiophen-2-yl]-1-methyl-prop-2-ynyl}-hydroxy urea |
| (r)-(+)-n-{3-[5-(4-fluorobenzyl)thien-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea |
| n-{(1r)-3-[5-(4-fluorobenzyl)thien-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea |
| bdbm50029781 |
| n-{(1r)-3-[5-(4-fluorobenzyl)thien-2-yl]-1-methylprop-2-ynyl}-n-hydroxyurea (abt-761) |
| 154355-76-7 |
| atreleuton (usan/inn) |
| D03010 |
| abt-761 |
| abbott-85761 |
| a-85761.0 |
| CHEMBL59356 , |
| a-85761 |
| via-2291 |
| 1-[(2r)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxyurea |
| unii-u301t88e1m |
| 1-((r)-3-(5-(p-fluorobenzyl)-2-thienyl)-1-methyl-2-propynyl-1-hydroxyurea |
| atreleuton [usan:inn] |
| abt 761 |
| via 2291 |
| ((r)-3-(5-(p-fluorobenzyl)-2-thienyl)-1-methyl-2-propynyl-1-hydroxyurea |
| u301t88e1m , |
| via2291 |
| 1-((r)-3-(5-(p-fluorobenzyl)-2-thienyl)-1-methyl-2-propynyl)-1-hydroxyurea |
| atreleuton [who-dd] |
| atreleuton [inn] |
| atreleuton [usan] |
| (r)-n-(3-(5-(4-fluorobenzyl) thien-2-yl)-1-methyl-2-propyn- yl)-n-hydroxy-urea |
| (r)-n-{3-[5-(4-fluorophenylmethyl)thien-2-yl]-1-methyl-2-propynyl)-n-hydroxyurea |
| (r)-n-{3-[5-(4-fluorophenylmethyl)thien-2-yl]-1-methyl-2-propynyl}-n-hydroxyurea |
| MMSNEKOTSJRTRI-LLVKDONJSA-N |
| SCHEMBL2108309 |
| DTXSID10165598 |
| DB12758 |
| NCGC00487341-02 |
| CS-0068291 |
| HY-117853 |
| nsc-781026 |
| nsc781026 |
| Q27290616 |
| 1-[(2r)-4-[5-[(4-fluorophenyl)methyl]thiophen-2-yl]but-3-yn-2-yl]-1-hydroxy-urea |
| AKOS040741178 |
Research Excerpts
Pharmacokinetics
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " ABT-761 has shown excellent oral bioavailability and an extended duration of plasma levels in man, and initial results for a single 200 mg po dose have shown a significant protective effect against exercise- and adenosine-induced bronchoconstriction in asthmatics [215839]." | ( ABT-761 (Abbott). Reid, JJ, 2001) | 0.31 |
| " Crossover design was also used to evaluate oral bioavailability of ABT-761 hemihydrate formulations in beagle dogs." | ( Effect of physicochemical and formulation variables on the in vivo absorption of ABT-761. Briskin, J; Fort, JJ; Gerhardt, AH; Mayer, P; Qiu, Y; Schilling, RJ; Trivedi, J, 2002) | 0.31 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Body weight, age, or body surface area can be used to provide dosing adjustment for ABT-761 in pediatric patients." | ( Pharmacokinetics of a novel 5-lipoxygenase inhibitor (ABT-761) in pediatric patients with asthma. Awni, WM; Chang, M; Drajesk, J; Dube, LM; Kearns, GL; Kemp, JP; Locke, CS; Wong, SL, ) | 0.13 |
| " ABT-761 is the follow-up compound for zileuton and, due to its increased potency, requires only once-daily dosing [187700]." | ( ABT-761 (Abbott). Reid, JJ, 2001) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (3)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 (µMol) | 0.0900 | 0.0001 | 1.6847 | 9.3200 | AID1724853 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 (µMol) | 0.0230 | 0.0046 | 2.0182 | 10.0000 | AID7057 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | IC50 (µMol) | 2.7000 | 0.0000 | 0.5450 | 9.1000 | AID1724852 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (38)
Molecular Functions (14)
Ceullar Components (14)
Bioassays (28)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID166410 | Compound was tested for in vitro inhibition against broken RBL-1. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID18431 | Oral bioavailability was determined in dog | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24 | (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. |
| AID180524 | In vivo rat anaphylaxis leukotriene formation on an oral dose of 200 micro mol/Kg | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13 | Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. |
| AID92880 | Inhibition of 5-lipoxygenase (5-LO) measured as LTB4 production in human whole blood stimulated with calcium ionophore (A23187). | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13 | Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. |
| AID92725 | Compound was tested for in vitro inhibition against human whole blood. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID1724857 | Solubility in pH 7.4 DPBS buffer | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase. |
| AID18432 | Oral bioavailability was determined in guinea pig | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24 | (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. |
| AID6970 | 5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4) | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24 | (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. |
| AID126490 | Rate of glucuronidation was determined using a microsomal preparation from the monkey liver tissue | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24 | (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. |
| AID177815 | Compound was evaluated in vivo for the rat anaphylaxis leukotriene formation at an oral dose of 30 umol/kg | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24 | (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. |
| AID178503 | Compound was tested for in vivo inhibition against rat peritoneal anaphylaxis. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID18434 | Oral bioavailability was determined in mouse | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24 | (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. |
| AID24351 | phase 1 oral half life at a dose 200 mg. (200 mg provided >95% inhibition of ex vivo stimulated LTB4 in blood up to 18 hour post dose) | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID7057 | Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells | 1998 | Journal of medicinal chemistry, Feb-12, Volume: 41, Issue:4 | Design, synthesis, and biological evaluation of conformationally constrained aci-reductone mimics of arachidonic acid. |
| AID18863 | Rate of glucuronidation (nmol/min/mg protein) in monkey microsomes | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13 | Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. |
| AID24073 | t1/2 in monkey after PO dose (2 umol/kg) | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13 | Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. |
| AID181942 | Percent inhibition of LTE4 formation in rats from peritoneal fluids at a dose of 200 micro mol/Kg | 1997 | Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13 | Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors. |
| AID6707 | In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay | 2004 | Bioorganic & medicinal chemistry letters, May-03, Volume: 14, Issue:9 | 5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity. |
| AID1724856 | Metabolic stability in rat liver microsomes assessed as compound remaining after 60 mins | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase. |
| AID1724852 | Inhibition of human sEH (1 to 555 residues) expressed in Escherichia coli BL21-(DE3) using PHOME substrate incubated for 30 to 45 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase. |
| AID18435 | Oral bioavailability in rat | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24 | (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. |
| AID75889 | Compound was tested for in vivo inhibition against gp antigen bronchospasm. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID18430 | Oral bioavailability was determined in cynomolgus monkey | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24 | (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor. |
| AID1553663 | Suppression of calcium ionophore-stimulated LTB4 production in CAD patient whole blood at 100 mg administered daily during phase 2 study for 12 weeks by ELISA relative to baseline | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9 | Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease. |
| AID1724853 | Inhibition of 5-LOX (unknown origin) expressed in Escherichia coli BL21-(DE3) pre-incubated for 15 mins before AA substrate addition and measured after 10 mins by HPLC/UV assay | 2020 | Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20 | Design, Synthesis, and Structure-Activity Relationship Studies of Dual Inhibitors of Soluble Epoxide Hydrolase and 5-Lipoxygenase. |
| AID160513 | Compound was tested for in vitro inhibition against human PMNL. | 1996 | Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14 | Modulators of leukotriene biosynthesis and receptor activation. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (26)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (57.69) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 15.86
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (15.86) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 12 (42.86%) | 5.53% |
| Reviews | 1 (3.57%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 15 (53.57%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||